Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
$8.04
+0.4%
$7.95
$5.15
$10.67
$1.09B1.161.37 million shs171,564 shs
Biotech Acquisition stock logo
BIOT
Biotech Acquisition
$10.15
-0.8%
$10.15
$8.30
$10.41
$291.81M-0.12244,605 shs44,400 shs
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
$8.29
-0.5%
$7.39
$4.79
$11.77
$1.32B1.511.46 million shs175,393 shs
OPKO Health, Inc. stock logo
OPK
OPKO Health
$1.39
+0.4%
$1.40
$1.19
$2.04
$1.10B1.424.23 million shs446,806 shs
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
+0.50%-1.84%-2.56%-7.73%+49.25%
Biotech Acquisition stock logo
BIOT
Biotech Acquisition
0.00%0.00%0.00%0.00%0.00%
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
+2.71%+20.03%-5.34%+16.50%+51.18%
OPKO Health, Inc. stock logo
OPK
OPKO Health
0.00%+5.34%-0.36%-28.87%-2.82%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
3.3174 of 5 stars
3.52.00.00.03.61.71.9
Biotech Acquisition stock logo
BIOT
Biotech Acquisition
N/AN/AN/AN/AN/AN/AN/AN/A
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
3.72 of 5 stars
3.41.00.04.12.72.50.0
OPKO Health, Inc. stock logo
OPK
OPKO Health
4.4964 of 5 stars
3.42.00.04.42.85.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
3.00
Buy$11.5043.12% Upside
Biotech Acquisition stock logo
BIOT
Biotech Acquisition
0.00
N/AN/AN/A
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
2.88
Moderate Buy$16.2596.14% Upside
OPKO Health, Inc. stock logo
OPK
OPKO Health
2.75
Moderate Buy$2.7598.56% Upside

Current Analyst Ratings Breakdown

Latest BIOT, OCUL, AUPH, and OPK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/29/2025
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$15.00
5/6/2025
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$15.00 ➝ $14.00
5/1/2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$2.25 ➝ $2.25
4/25/2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral
4/8/2025
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform
4/8/2025
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
4/7/2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$3.00 ➝ $3.00
3/19/2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$3.00 ➝ $3.00
3/18/2025
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$17.00
3/12/2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$3.00 ➝ $3.00
3/12/2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$2.25 ➝ $2.25
(Data available from 6/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
$247.30M4.39N/AN/A$2.63 per share3.06
Biotech Acquisition stock logo
BIOT
Biotech Acquisition
N/AN/AN/AN/A($0.95) per shareN/A
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
$59.65M22.13N/AN/A$0.79 per share10.49
OPKO Health, Inc. stock logo
OPK
OPKO Health
$689.41M1.59N/AN/A$1.80 per share0.77
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
-$78.02M$0.28N/A14.35N/A-10.23%-4.41%-3.07%7/30/2025 (Estimated)
Biotech Acquisition stock logo
BIOT
Biotech Acquisition
-$6.86MN/A0.00N/AN/A-42.22%3.48%N/A
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
-$80.74M-$1.15N/AN/AN/A-283.74%-45.18%-30.87%8/6/2025 (Estimated)
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$188.86M-$0.07N/AN/AN/A-18.65%-9.76%-6.46%8/6/2025 (Estimated)

Latest BIOT, OCUL, AUPH, and OPK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2025Q1 2025
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
$0.08$0.16+$0.08$0.16$61.06 million$62.47 million
4/30/2025Q1 2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$0.07-$0.10-$0.03-$0.10$163.13 million$149.90 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
N/AN/AN/AN/AN/A
Biotech Acquisition stock logo
BIOT
Biotech Acquisition
N/AN/AN/AN/AN/A
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
N/AN/AN/AN/AN/A
OPKO Health, Inc. stock logo
OPK
OPKO Health
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
0.17
5.60
5.11
Biotech Acquisition stock logo
BIOT
Biotech Acquisition
N/A
0.03
0.03
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
0.19
13.01
12.94
OPKO Health, Inc. stock logo
OPK
OPKO Health
0.30
2.97
2.69

Institutional Ownership

CompanyInstitutional Ownership
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
36.83%
Biotech Acquisition stock logo
BIOT
Biotech Acquisition
80.01%
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
59.21%
OPKO Health, Inc. stock logo
OPK
OPKO Health
64.63%

Insider Ownership

CompanyInsider Ownership
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
12.20%
Biotech Acquisition stock logo
BIOT
Biotech Acquisition
19.00%
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
2.30%
OPKO Health, Inc. stock logo
OPK
OPKO Health
49.69%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
300135.10 million137.02 millionOptionable
Biotech Acquisition stock logo
BIOT
Biotech Acquisition
428.75 million23.29 millionNot Optionable
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
230159.30 million151.71 millionOptionable
OPKO Health, Inc. stock logo
OPK
OPKO Health
4,200793.05 million359.94 millionOptionable

Recent News About These Companies

Q1 2025 OPKO Health Inc Earnings Call
OPKO Health: Q1 Earnings Snapshot

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Aurinia Pharmaceuticals stock logo

Aurinia Pharmaceuticals NASDAQ:AUPH

$8.04 +0.04 (+0.44%)
As of 10:49 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

Biotech Acquisition stock logo

Biotech Acquisition NASDAQ:BIOT

Biotech Acquisition Company does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or other business combination with one or more businesses. The company was incorporated in 2020 and is based in New York, New York.

Ocular Therapeutix stock logo

Ocular Therapeutix NASDAQ:OCUL

$8.28 -0.05 (-0.54%)
As of 10:50 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

OPKO Health stock logo

OPKO Health NASDAQ:OPK

$1.38 +0.01 (+0.36%)
As of 10:50 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.